PRODUCTION OF MACROPHAGE AND INTERLEUKIN-8 MIGRATION INHIBITION FACTOR IN CHILDREN AND ADOLESCENTS SUFFERING FROM DESTRUCTIVE PULMONARY TUBERCULOSIS

The goal of the study is to assess the changes in spontaneous and antigen-induced production of macrophages and interleukin-8 in destructive tuberculosis patients during the intensive phase of treatment. The cultures of whole blood of 38 destructive tuberculosis patients were used as a source of macrophages and interleukin-8 production, and the patients were divided depending on procalcitonin semiquantitative test (BRAHMS PCT-Q) results into the group of PCT+ (15 patients) and the group of PCT- (23 patients). Production of macrophages and interleukin-8 were assessed in the cultured blood for 20-22 hours. Antigen-induced synthesis of macrophages was assessed after adding 20 mkg/ml of PPD or 1 mkg/ml of ESAT 6/CFP 10. Production of cytokines was tested by enzyme immunoassay. It has been found that the rates of spontaneous production of macrophages or interleukin-8 in the cultured blood reflect the changes in the production of these factors and can be used without consideration of antigen-induced synthesis; spontaneous production of macrophages in patients with positive test for PCT confidently decreases and production of IL-8 confidently goes up by the 2nd month of anti-tuberculosis chemotherapy; changes in spontaneous production of macrophages di}er in patients with the various course of destructive tuberculosis (favorable, torpid, progressing). In the favorable course of the disease production of macrophages increases, in torpid or progressing ones – goes down or stays unchanged.

macrophages migration inhibition factors, interleukin-8, children, adolescents, destructive pulmonary tuberculosis

1. Averbakh M.M., Gergert V.Ya., Litvinov V.I. Povyshennaya chuvstvitelnost zamedlennogo tipa i infektsionny protsess. [Delayed sensitivity and infectious process]. Moscow, Meditsina Publ., 1974,

2. Ovsyankina E.S., Panova L.V., Averbakh M.M. et  al. Experience of  using procalcitonin testing as a marker for severe tuberculous infection in children. Tub., 2013, no. 6, pp. 63-64. (In Russ.)

3. Assicot M., Gendrel D., Carsin H. et al. High serum procalcitonin concentrations in patient with sepsis and infection. Lancet, 1993, vol. 341, pp. 515-518.

4. Baugh J.A., Donnelly S.C. Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J. Endocrinol., 2003, vol. 197, pp. 15-23.

5. Bernhagen J., Calandra T., Bucala R. Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. J. Mol. Med., 1998. vol. 7, pp. 151-161.

6. Bhattacharjya S. De novo designed lipopolysaccharide binding peptides: structure based development of antiendotoxic and antimicrobial drugs. Curr. Med. Che., 2010, vol. 17, pp. 3080-3093.

7. Bloom B.R., Bennett B. Mechanism of  a  reaction in  vitro associated with  delayed-type hypersensitivity. Science, 1966, vol. 153, pp. 80-82.

8. Das R., Koo M., Bae Hoon Ki B. et al. Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium tuberculosis. PNAS, 2013, E2997-E3006., doi/10.1073/pnas.1301128110

9. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. AcadSci. USA, 1966, vol. 56, pp. 72-77.

10. Ferro E.A., Mineo J.R., Ietta F. et al. Macrophage migration inhibition factor is up-regulated in human first-trimester placenta stimulated by soluble antigen of Toxoplasma gondii, resulting in increased monocyte adhesion on villous explants. Am., J. Pathol., 2008, vol. 172, pp. 540-548.

11. Hoovers J.M.N., Redeker E., Speleman F. High-resolution chromosomal localization of the human CALCITONIN /CGRP/ IAPP gene family members. Genomics, 1993, vol. 15. pp. 525-529.

12. Huang S.L., Lee H.C., Yu C.W. et al. Value of procalcitonin in differentiating pulmonary tuberculosis from other pulmonary infections: a meta-analysis. Int. J. Tuberc. Lung Dis., 2014, vol. 18, no. 4, pp. 470-477.

13. Kibiki G.S., van der Ven A.J., Geurts-Moespot A. et al. Serum and BAL macrophage migration inhibitory factor levels in HIV infected Tanzanians with pulmonary tuberculosis or other lung diseases. Clin.Immunol., 2007, vol. 123, pp. 60-65.

14. Le Moullec J.M., Jullienne A., Chenais J. et al. The complete sequence of human preprocalcitonin. FEBS, 1984, vol. 167, pp. 93-97.

15. Seldenfijik C., Drexhage H., Meuwissen S. et  al. T-cell immune reaction (in macrophage inhibition factor assay) against M. paratuberculosis, M. kansasii, M. avium, M. tuberculosis in patients with chronic inflammatory bowel disease. Gut., 1990, vol. 31, pp. 529-535.

16. Sobierajski J., Hendgen-Cotta U.B., Luedike P. et al. Assessment of macrophage migration inhibitory factor in humans: protocol for accurate and reproducible levels. Free Radic. Biol. Med., 2013, vol. 63, pp. 236-242. 17. Yamada G., Shijubo N., Takagi-Takahashi Y. et al. Elevated levels of serum macrophage migration inhibitory factor in patients with pulmonary tuberculosis. Clin. Immunol., 2002, vol. 104, pp. 123-127.